Pharmacokinetic Study of E7080/Lenvatinib in Chinese Subjects With Solid Tumor
Status:
Completed
Trial end date:
2021-08-27
Target enrollment:
Participant gender:
Summary
Study E7080-C086-108 is an open-label, single- and multiple-dose pharmacokinetic (PK) study
of lenvatinib (administered orally, once a day [QD]) in Chinese participants with solid
tumor. A total of 12 participants will be enrolled to evaluate the PK of 24 milligrams (mg)
QD dosing of lenvatinib.